These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1804931)

  • 21. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined oral/nasal immunization protects mice from Sendai virus infection.
    Nedrud JG; Liang XP; Hague N; Lamm ME
    J Immunol; 1987 Nov; 139(10):3484-92. PubMed ID: 2824609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.
    Valosky J; Hishiki H; Zaoutis TE; Coffin SE
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):171-9. PubMed ID: 15643003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).
    Murphy BR; Prince GA; Collins PL; Hildreth SW; Paradiso PR
    Vaccine; 1991 Mar; 9(3):185-9. PubMed ID: 2042390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
    Wyatt LS; Whitehead SS; Venanzi KA; Murphy BR; Moss B
    Vaccine; 1999 Oct; 18(5-6):392-7. PubMed ID: 10519927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection of mice from rabies by intranasal immunization with inactivated rabies virus.
    Yoneda A; Tuchiya K; Takashima Y; Arakawa T; Tsuji N; Hayashi Y; Matsumoto Y
    Exp Anim; 2008 Jan; 57(1):1-9. PubMed ID: 18256513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model.
    Singh SR; Dennis VA; Carter CL; Pillai SR; Jefferson A; Sahi SV; Moore EG
    Vaccine; 2007 Aug; 25(33):6211-23. PubMed ID: 17629376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes.
    Hu KF; Ekström J; Merza M; Lövgren-Bengtsson K; Morein B
    Med Microbiol Immunol; 1999 May; 187(4):191-8. PubMed ID: 10363675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.
    Gonzalez IM; Karron RA; Eichelberger M; Walsh EE; Delagarza VW; Bennett R; Chanock RM; Murphy BR; Clements-Mann ML; Falsey AR
    Vaccine; 2000 Mar; 18(17):1763-72. PubMed ID: 10699324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice.
    Singh SR; Dennis VA; Carter CL; Pillai SR; Moore EG
    Viral Immunol; 2007; 20(2):261-75. PubMed ID: 17603843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines.
    Bastien N; Trudel M; Simard C
    Vaccine; 1999 Feb; 17(7-8):832-6. PubMed ID: 10067688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.
    Bembridge GP; Garcia-Beato R; López JA; Melero JA; Taylor G
    J Immunol; 1998 Sep; 161(5):2473-80. PubMed ID: 9725246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.
    Hancock GE; Smith JD; Heers KM
    Viral Immunol; 2000; 13(1):57-72. PubMed ID: 10733169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein.
    Smucny JJ; Kelly EP; Macarthy PO; King AD
    Am J Trop Med Hyg; 1995 Oct; 53(4):432-7. PubMed ID: 7485699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The envelope proteins from purified respiratory syncytial virus protect mice from intranasal virus challenge.
    Levine S; Dillman TR; Montgomery PC
    Proc Soc Exp Biol Med; 1989 Apr; 190(4):349-56. PubMed ID: 2928348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.
    Goetsch L; Plotnicky-Gilquin H; Champion T; Beck A; Corvaïa N; Stâhl S; Bonnefoy JY; Nguyen TN; Power UF
    Vaccine; 2000 Jun; 18(24):2735-42. PubMed ID: 10781861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.
    Vaux-Peretz F; Chapsal JM; Meignier B
    Vaccine; 1992; 10(2):113-8. PubMed ID: 1539464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
    Hsu KH; Lubeck MD; Davis AR; Bhat RA; Selling BH; Bhat BM; Mizutani S; Murphy BR; Collins PL; Chanock RM
    J Infect Dis; 1992 Oct; 166(4):769-75. PubMed ID: 1527411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.